StarMab, Inc. has developed a cutting-edge technology platform focused on the creation of specific multifunctional antibody biopharmaceuticals. Central to their innovation is the VHH nanobody discovery platform, known as StarMab VHH, which enables the efficient and rapid screening of VHH nanobody molecules that exhibit strong therapeutic efficacy and favorable drug-like properties. This platform allows for the design of flexible multi-antibody constructs by linking different VHH antibody fragments, which can be tailored to enhance antibody affinity and selectively activate immune cell networks to target and destroy tumor cells. The company emphasizes the simplicity and stability of their nanobody structures, which contribute to high expression levels and purification yields.

In addition to their VHH discovery capabilities, StarMab has established an innovative VHH antibody engineering optimization platform. This platform focuses on enhancing the affinity and functionality of VHH molecules while minimizing risks associated with post-translational modifications. StarMab's technology also addresses challenges in developing multispecific antibodies, such as stability and manufacturability. Their pipeline includes promising candidates like SM3321, which has received IND approval in both the U.S. and China and is currently undergoing clinical trials, demonstrating significant anti-tumor effects and safety. Overall, StarMab's advanced platforms are designed to streamline the drug development process, reduce costs, and accelerate the delivery of novel therapies to patients.

China

Shuoxing Biotech is a biopharmaceutical company committed to the development of efficient and low-toxic multifunctional antibody medicines. Shuoxing Biotech is a biotechnology company based in China that has raised an undisclosed amount of money in funding.

StarMab, Inc

Company Details